@dansfera · Long IOVA · The Analysts

This shows you how tough it is to sustain promising science. This is why $iova latest quarterly earnings was a de risking event for me. Ultimately biotech is a business and should be treated as such. Grateful for this 💎

Yair Einhorn@yaireinhorn

1/🚨🚨WOW! What a huge disappointment for the entire CRISPR Gene Editing and the Allogeneic Cell Therapy fields following $CRBU announcement that it is discontinuing all of its clinical R&D activities and is literally shutting down its operations. @CaribouBio plans to discontinue h

WOW! What a huge disappointment for the entire CRISPR Gene Editing and the Allogeneic Cell Therapy fields following Caribou’s announcement that it is discontinuing all of its clinical R&D activities and is literally shutting down its operations. Caribou bio plans to discontinue the clinical trials and any further development activities of its two leading allogeneic CAR-T cell therapy programs - vispacabtagene regedleucel (vispa-cel / CB-010) and CB-011, as well as a substantial reduction of the Company’s workforce and other cost reduction measures.

Read asLong IOVA

Since the call−26#68 → #94

#94 of 176 rankedThe analyst's rank today

Medium · 0.84Confidence

Wed, Oct 7Tweeted

Thu, Oct 8 closeCounted from

3% of the basket · day 12fades out by Nov 18

Rank per close

#68

Oct 8

#76

Oct 11

#60

Oct 12

#50

Oct 13

#69

Oct 14

#73

Oct 15

#75

Oct 18

#94

Oct 19